Sareum Holdings plc
Research Sareum Holdings plc (SAR.L) on Bullrun: market cap GBX 4.19B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSAR.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 4.19B
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 4.44M
- Free cash flow-GBP 2.55M
Valuation Snapshot
latest market cap is GBX 4.19B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 4.44M | -GBP 2.55M | n/a | -0.02 | GBP 3.55M | n/a | GBP 2.28M |
| FY2024 | GBP 0 | -GBP 3.42M | -GBP 3.92M | n/a | -0.04 | GBP 1.46M | n/a | GBP 2.11M |
| FY2023 | GBP 0 | -GBP 3.19M | -GBP 3.27M | n/a | -0.05 | GBP 994.00K | n/a | GBP 1.15M |
| FY2022 | GBP 0 | -GBP 2.17M | -GBP 2.13M | n/a | -0.03 | GBP 4.26M | n/a | GBP 4.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 4.19B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Sareum Holdings plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sareum Holdings plc's market cap?
Sareum Holdings plc's market capitalization is GBX 4.19B.
What does Sareum Holdings plc do?
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases.